Entelos has ongoing internal drug programs for rheumatoid arthritis and women's health. It is also developing an oncology model and is collaborating with the US Food and Drug Administration to develop a model of drug-induced liver injury.
J&J Pharma R&D Taps Entelos for In Silico Studies of Type-2 Diabetes Therapies
Dec 19, 2007
NEW YORK (GenomeWeb News) - Entelos said today that has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development to use its predictive computer models of human physiology to study new therapies for type-2 diabetes.
Under the agreement, Entelos will use its in silico “virtual patients” to discover and evaluate therapies for the disease.
The companies signed a collaborative agreement in March 2006 covering multiple therapeutic areas, but did not provide further details at the time.
Financial terms of the agreement were not released.
Entelos' CEO, James Karis, said the agreement is part of the company's strategy to offer its predictive services "in chronic disease areas where multiple drugs, treatment choices, and large differences between patients make it difficult for health-care providers to select the best treatments."